Investigation of the Serum Mucoprotein 3 (MUC3) Protein Levels in Gestational Hypertensive Disease
NCT ID: NCT04421183
Last Updated: 2020-06-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
80 participants
OBSERVATIONAL
2010-06-01
2011-01-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Proteomics/Modifier Based on Mass Spectrometry Reveals the Pathogenesis of Eclampsia During Pregnancy and the Screening of Disease Markers
NCT04833881
Maternal Serum Markers Predicting Preeclampsia At Early Gestations
NCT05131282
Maternal Serum Stathmin-1 Levels in Preeclampsia
NCT06481683
Pepsinogen-1 Serum Levels in Hyperemesis Gravidarum
NCT06581796
Angiogenic Factors in the Conservative Management of Gestational Hypertension
NCT06123377
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
preeclampsia
draw blood
draw blood from the all of patients
4
normal pregnancy without complication
draw blood
draw blood from the all of patients
2
hellp
draw blood
draw blood from the all of patients
3
eclampsia
draw blood
draw blood from the all of patients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
draw blood
draw blood from the all of patients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* According to ACOG 2002, pregnancy meets the criteria of hypertensive diseases \[1\], The diagnosis of HELLP syndrome was made according to the criteria described by Sibai. These; abnormal peripheral smear, schistocyte in the peripheral smear, lactate dehydrogenase \> 600 U / L, hemolysis, total bilirubin\> 1.2 mg / dl, AST\> 70 U / L, platelet count \<100,000mm3.
* When the demographic characteristics and CVs of all cases were questioned in the initial evaluation, not having chronic inflammation or acute infection, not having any systemic disease, recurrent pregnancy loss, thrombophilia, antiphospholipid antibody syndrome,
* Not smoking, No history of cancer, No multiple pregnancies
* Not using antihypertensive, anticoagulant, NSAID, corticosteroid or antiplatelet and antiepileptic drugs
Exclusion Criteria
* smoking,history of cancer, multiple pregnancies
18 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Karadeniz Technical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Suleyman Guven
professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Karadeniz Technique University
Trabzon, Ortahisar, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MUC 3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.